Altimmune (ALT) | Pemvidutide MASH Breakthrough & CEO Catalyst

Altimmune (ALT)

Pemvidutide MASH Breakthrough and CEO Catalyst: Multi-Year Inflection Point

Positive momentum — updated December 3, 2025

NASDAQ: ALT | Pemvidutide (Dual GLP-1/Glucagon Agonist) | Street targets generally in the mid-teens to high-twenties range

Executive Summary — A Positive Turning Point

Altimmune is entering a pivotal phase with several bullish drivers converging through Q4 2025 and into 2026:

CEO Transition (January 1, 2026): Jerry Durso (former Intercept CEO, long career at Sanofi) becomes CEO. His background aligns strongly with commercialization, reimbursement strategy, and liver/metabolic drug launches.
IMPACT Phase 2b MASH: At 24 weeks, MASH resolution without fibrosis worsening reached 59.1 percent (1.2 mg) and 52.1 percent (1.8 mg) vs 19.1 percent placebo; weight loss of 5.0–6.2 percent; liver fat reduction of 58–62.8 percent and meaningful fibrosis signals using AI-assisted analysis.
Key upcoming milestones: 48-week data (Q4 2025), End-of-Phase 2 FDA meeting (Q4 2025), and final Phase 3 trial design for MASH.
Financial position: Approximately 210.8 million USD in cash (Q3 2025), burn of 20–22 million per quarter, plus a 125 million USD Hercules credit line. Cash runway estimated at more than two years.
Addressable market: MASH alone represents a multibillion-dollar market. The dual GLP-1/glucagon mechanism positions pemvidutide also for weight management and cardiometabolic indications.

1. The CEO Catalyst: Jerry Durso

Why This CEO Change Matters

Community Sentiment on the New CEO

Most active traders interpret the leadership change as follows:

Durso is seen as a serious, execution-focused leader with significant experience in liver disease and commercial strategy.

His background at Intercept and network built at Sanofi fuel speculation about potential partnerships.

Jerry Durso — Background (Verified Information)

Item	Details
Industry experience	More than 30 years in life sciences, focused on commercial strategy, metabolic franchises and rare diseases.
Most recent role	CEO of Intercept Pharmaceuticals until its acquisition by Alfasigma.
Liver disease track record	Hands-on experience with PBC, regulatory complexities, pricing and market access.
Career at Sanofi	Over 20 years in senior commercial roles, including Head of U.S. Commercial Operations.
Entry into Altimmune	Joined Board in 2025, became Chairman and later CEO effective January 1, 2026.

Verified data: Information sourced from Altimmune’s official CEO Transition announcement and public Intercept/Sanofi biographies.

2. Pemvidutide MASH Program — IMPACT Phase 2b Results

2.1 Summary of the 24-Week Results

MASH Resolution (24w)

59 percent (1.2 mg)

Liver Fat Reduction

58–63 percent

Average Weight Loss

5.0–6.2 percent

Fibrosis Reduction (AI, ≥60 percent)

30.6 percent (1.8 mg)

Endpoint (24 weeks)	Pemvidutide 1.2 mg	Pemvidutide 1.8 mg	Placebo
MASH Resolution without Fibrosis Worsening	59.1 percent	52.1 percent	19.1 percent
Fibrosis Improvement without MASH Worsening	31.8 percent	34.5 percent	25.9 percent
Liver Fat Reduction (MRI-PDFF)	58.0 percent	62.8 percent	16.2 percent
Weight Loss	-5.0 percent	-6.2 percent	-1.0 percent
Participants ≥60 percent Fibrosis Reduction (AI)	11.9 percent	30.6 percent	8.2 percent

Data sourced from Altimmune’s official IMPACT Phase 2b topline release (June 2025).

2.2 Clinical Relevance vs Competitors

Key Observations

High MASH resolution: 52–59 percent places pemvidutide at the upper end of industry outcomes for 24 weeks.
Fibrosis signals: Primary fibrosis endpoint not statistically significant, but AI-based analysis shows strong differentiation (30.6 vs 8.2 percent).
Dual liver + metabolic profile: Strong liver fat reduction, weight loss and NIT improvements.
Safety and tolerability: Very low discontinuation rates, no drug-related SAEs.

2.3 Upcoming MASH Catalysts

Catalyst	Estimated Timing	Impact
48-Week IMPACT Data	Q4 2025	Durability of MASH resolution; extended fibrosis data; expanded safety window.
FDA End-of-Phase 2 Meeting	Q4 2025	Alignment on Phase 3 structure; key to reduce regulatory uncertainty.
Phase 3 Initiation	2026	Potentially major sentiment driver depending on design and timelines.

3. Financial Position: Cash & Runway

Cash & Equivalents (Q3 2025)

210.8M USD

Estimated Quarterly Burn

20–22M

Hercules Credit Facility

125M USD

Estimated Runway

Over 2 Years

Metric	Q3 2025	Approx. Q3 2024
Cash & Equivalents	210.8M USD	Approx. 132M USD
Net Loss (Quarterly)	Approx. -19M USD	-15M USD
R&D Spend	Approx. 15M USD	12M USD
Total Assets	Approx. 265M USD	Approx. 150M USD

Financial Strength Consideration

Cash + credit facility provides enough buffer for Phase 3 initiation and major clinical milestones.
A more aggressive strategy may require future financing, depending on clinical expansion.

Verified data: Figures sourced from Altimmune’s Q3 2025 earnings release and Form 10-Q.

4. Market Performance and Analyst Consensus

4.1 Market Snapshot (December 3, 2025)

Metric	Indicative Value
Current Price	Approx. 5.12 USD (+7–8 percent on the day)
52-Week Range	2.90 – 10.88 USD
Market Cap	Approx. 530–540M USD
Volume Today	1.8–1.9M shares
YTD Performance	Weak, with significant drawdown from yearly highs

4.2 Analyst Consensus and Price Targets

Firm	Rating	Target	Upside vs 5.12 USD
Piper Sandler	Overweight / Buy	Approx. 25 USD	Approx. +380 percent
Jefferies	Buy	High-twenties	Approx. +400 percent
H.C. Wainwright	Buy	Approx. 12 USD	Approx. +130 percent
Stifel Nicolaus	Buy	Approx. 18 USD	Approx. +250 percent
Other brokers	Buy / Outperform	Mid-teens to low-twenties	Significant re-rating potential
Consensus Range		Mid-teens / low-twenties	Large theoretical upside

Takeaway from Sell-Side Analysts

Analysts remain broadly bullish, but the stock trades at a discount due to execution concerns.
If Phase 3 confirms the Phase 2b profile, valuation could move sharply higher.

5. Trader Sentiment & Online Discussion

Common Themes Among Active Traders

Most frequent interpretations include:

Many see CEO Durso + IMPACT results + FDA meeting as aligned catalysts indicating confidence from the Board.

Partnership speculation remains elevated due to Durso’s network at Sanofi.

Pemvidutide is increasingly viewed as a dual-use asset (MASH + weight), expanding market potential.

In short: sentiment is constructive but aware of clinical and regulatory risks.

6. Valuation Framework: Bull, Base and Bear

Bull Case

20 – 28 USD

Assumptions: Strong Phase 3 confirming MASH resolution and fibrosis improvement; accelerated approval potential; partnership or acquisition; billion-plus sales potential.

Base Case

12 – 18 USD

Assumptions: Phase 3 positive but with mixed signals; approval achieved; moderate sales ramp.

Bear Case

2 – 6 USD

Assumptions: Phase 3 fails; safety issues; FDA requests further studies; dilution likely.

7. Key Catalysts Ahead (Q4 2025 – 2026)

Summary of Catalysts

Q4 2025: IMPACT 48-week data (durability, fibrosis, safety).
Q4 2025: FDA End-of-Phase 2 meeting.
January 1, 2026: Durso becomes CEO.
2026: Phase 3 initiation and pipeline updates.

8. Disclaimer & Key Risk Factors

Important Disclaimer

This report is for educational and informational purposes only. It is not investment advice and does not constitute a recommendation to buy or sell any security.

Biotech risk: Clinical-stage biotech companies carry very high inherent risk.
Clinical and regulatory risk: Positive Phase 2b results do not guarantee Phase 3 success.
Competitive risk: MASH is a highly competitive space.
Dilution risk: Additional financing remains possible.
Market data variability: Price, volumes and market cap refer to December 3, 2025.

9. Sources & Useful Links

Altimmune — IMPACT Phase 2b topline results (June 2025).
Altimmune — Q3 2025 financial results and SEC filings.
Altimmune — CEO Transition announcement.
ALT on Finviz
ALT page on Seeking Alpha
ALT on StockTwits
Altimmune official website

Support the Merlintrader trading Blog

If this report is helpful and you want to support the site remaining free for everyone, you can contribute via PayPal.

Donate via PayPal

Author’s Personal Note (EN)

I spend many hours reading SEC filings, official press releases and reliable news sources to understand what truly moves biotech stocks. This report reflects my interpretation of the available data and may contain limitations or errors. If you spot any inaccuracies, constructive corrections are welcome.

Nothing here should be taken as financial advice. Always conduct your own research and consult a qualified professional when needed.

Author’s Personal Note (IT)

Passo molte ore su SEC filing, comunicati ufficiali e fonti affidabili per capire cosa muove realmente i titoli biotech. Questo report rappresenta la mia lettura dei dati e può contenere limiti o errori. Se noti imprecisioni, ogni segnalazione costruttiva è benvenuta.

Nulla qui è una consulenza finanziaria. Verifica sempre le informazioni e confrontati con un professionista quando necessario.

Authors: Merlintrader and Jane.

ALT – Altimmune | Merlintrader trading Blog

ALT (Altimmune)

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author's note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell'autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull'uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l'organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall'autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell'autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L'autore non è un consulente finanziario abilitato all'esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L'autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l'attenzione dell'analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l'autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall'utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Se trovi utili questi report e vuoi sostenere il progetto, puoi fare una donazione volontaria una tantum tramite PayPal o Buy Me a Coffee. È un aiuto concreto per coprire i costi di dati, strumenti e hosting, così i contenuti possono restare indipendenti e liberamente accessibili.

Strumenti e piattaforme di ricerca usati in questo report

Qui sotto trovi una selezione di strumenti e piattaforme che uso personalmente per seguire prezzi, catalyst, fondamentali e sentiment. I link sono forniti solo per trasparenza e comodità del lettore.

Finviz Elite – screener avanzato e piattaforma grafica, usato per heatmap, performance relative e contesto tecnico.
ChartsWatcher – scanner real-time di nuova generazione per il mercato azionario USA. Lo uso per monitorare momentum intraday, picchi di volume e alert cromatici sui pattern.
Stocktwits – flusso social focalizzato sui ticker, usato solo come indicatore di sentiment e attività, non come fonte di raccomandazioni di investimento.
Monica.im – assistente AI usato per report leggeri, drafting e ricerche veloci; utile per strutturare note e prime analisi insieme al lavoro di approfondimento pubblicato su Merlintrader.
Medved Trader – piattaforma professionale di trading e charting usata per esecuzione real-time, order-flow e analisi intraday dettagliata. Nessun affiliate link; è citata perché fa parte del workflow operativo reale.
Merlintrader trading Blog – la casa dei report focalizzati sul biotech, delle dashboard e degli articoli educativi che approfondiscono i temi menzionati in questo documento.

Alcuni dei link sopra indicati sono link affiliati. Se decidi di iscriverti o acquistare tramite uno di essi, Merlintrader potrebbe ricevere una piccola commissione senza costi aggiuntivi per te. Questo aiuta a mantenere il sito online e i report liberamente accessibili. Non hai alcun obbligo di usare questi link: scegli sempre la soluzione che ritieni più adatta alle tue esigenze e alla tua valutazione personale.

Le informazioni legali complete, le avvertenze sui rischi e le condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali di Merlintrader:

Versione italiana: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

Le stesse pagine includono anche il testo corrispondente in inglese o un equivalente inglese delle principali avvertenze legali, così anche i lettori internazionali possono consultare le informazioni essenziali su rischi e condizioni d'uso.

Biotech Catalyst Calendar

Per una visione più ampia e continuamente aggiornata dei prossimi catalyst biotech (date PDUFA, principali letture cliniche, eventi regolatori e conferenze chiave), puoi consultare il calendario dedicato su Merlintrader.

Apri il Biotech Catalyst Calendar